CRISPR-Cas9 repairs genetic mutation in human embryos
"Well thought through and brilliantly executed" study shows different DNA-repair mechanism in embryos compared to iPSCs
List view / Grid view
Articles
Inflammatory biomarkers as a herbal anti-arthritic drug discovery tool
Rheumatoid arthritis (RA) is joint-related, immune-based inflammatory disarray that affects almost 1% of the world’s population. The most evidenced pathogenesis is T-cell activation, which leads to clusters of differentiation (CD) in the T-cells and concurrently increases various inflammatory biomarkers.
Phenotypic and target-based screening: complementary or competing?
The screening of drug targets against compound libraries is now a mature and validated approach to identifying the chemical starting points of drugs...
Using clinical drug resistance to kill cancer cells
Drug resistance is a significant therapeutic problem, from infectious diseases to cancer. Given a large enough population of genetically varying target cells, the emergence of drug resistance is not surprising and is even unavoidable...
Development by design methodology: the key to successful manufacturing of patient-specific cell therapies
Recognised as the next wave of medicine, cell therapies have made significant strides over the last several years. But such advancements can present unique challenges, especially as more products move out of the clinic and toward commercialisation. And unlike typical pharmaceuticals, cell therapies rely heavily on the manufacturing process to…
David F Fischer on target screening
Drug Target Review editor Steve Bremer asks David F Fischer for his views on target discovery and validation in drug discovery. David F Fischer, PhD, is Executive Director Biology at Charles River...
Using venoms to uncover new targets in drug discovery
A range of drugs used in modern medicine are derived from animal venoms, and Steve Trim from Venomtech discusses how natural selection has made venoms particularly useful tools for uncovering new targets in drug discovery...
New drug targets identified to defend against chlamydia infections using CRISPR and stem cells
Human induced pluripotent stem cell derived macrophages (iPSDMs) provide a cell-based model system to study chlamydia infection in the laboratory. Amy Yeung from Wellcome Trust Sanger Institute explains how she used this model in combination with CRISPR-Cas 9 technology to explore the potential of the two genes, IRF5 and IL10RA,…
Intracellular target validation in cellular systems … using peptides!
Paul Grant from Venomtech suggests that because animal venoms contain proteins and peptides that disrupt cell membrane integrity, they offer a new approach to drug discovery...
Q&A: The role of disease focused foundations in bridging the drug discovery and development gap
Bio 2017 opens this week and Drug Target Review’s Niamh Marriott spoke with Richard Soll, Senior Vice President, Research Service Division, WuXi AppTec and Salvatore La Rosa, Vice President Research and Development, Children’s Tumor Foundation, to get their perspectives on one of the event’s most pressing trends. Both will be…
Plant-Mediated Modulation of Reactive Oxygen Species (ROS) Homeostasis
A review of Keap1/Nrf2 modulation of ROS homeostasis, and its pivotal role in the pathogenesis of cancer, Type 2 diabetes mellitus & neurological disorders.
Targets In-Depth Focus 2017
Included in this Targets In-Depth Focus: Intracellular target validation in cellular systems; New drug targets identified to defend against chlamydia infections using CRISPR and stem cells; Novel solutions for tough targets with real bite...
Stem Cells In-Depth Focus 2017
Included in this Stem Cells In-Depth Focus: Translating discoveries into therapies; The key to successful manufacturing of patient-specific cell therapies; Interview with Alessandro Prigione and James Adjaye...
Screening In-Depth Focus 2017
Included in this Screening In-Depth Focus: Phenotypic and target-based screening; Killing cancer cells using clinical drug resistance; Inflammatory biomarkers as a herbal anti-arthritic drug discovery tool...
Insights from discovery through clinical efficacy to support a new class of therapeutics in Alzheimer’s disease
Research into innovative small molecule therapeutics with disease modifying potential in Alzheimer’s disease (AD) has been conducted at Alzheon since 2013.